Hepatitis C Pediatric Trials Should Avoid Liver Biopsy As Endpoint
Executive Summary
Pediatric hepatitis C trials should avoid liver biopsies as an efficacy endpoint in the near term, committee guest Karen Lindsay, MD, University of Southern California, told a meeting of FDA's Anti-Infective Drugs Advisory Committee/Pediatric Subcommittee April 23.